Benzinga's Top #PreMarket Losers

shares fell 24.28% to $6.86 in pre-market trading after the company provided an update on IND for ARC-520 Phase 2b study.

fell 9.32% to $12.65 in pre-market trading after the company announced long-term outcomes through 168 weeks from phase IIb study of eteplirsen in Duchenne muscular dystrophy. Sarepta Therapeutics said results of 6-minute walk test at 168 weeks showed continued ambulation across all patients evaluable on the test.

shares dropped 6.18% to $91.00 in pre-market trading after the company lowered its Q4 sales outlook.

shares dropped 5.90% to $97.35 in pre-market trading after the company reported holiday-period sales results and lowered its FY outlook. In the Americas, Tiffany's total sales on a constant-exchange-rate basis were equal to the earlier year.

shares declined 1.48% to $214.26 in pre-market trading after the company agreed to buy

for $5.2 billion, or $46 per share.